Skip to main content
SpringerLink
Log in

Acute acalculous cholecystitis associated with alemtuzumab

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Croteau D, et al. Acute acalculous cholecystitis: A new safety risk for patients with MS treated with alemtuzumab. Neurology : 30 Mar 2018. Available from: URL: http://doi.org/10.1212/WNL.0000000000005422.

  2. Muraro PA, et al. Rare side effects of alemtuzumab remind us of the need for postmarketing surveillance. Neurology : 30 Mar 2018. Available from: URL: http://doi.org/10.1212/WNL.0000000000005409.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Acute acalculous cholecystitis associated with alemtuzumab. Reactions Weekly 1697, 3 (2018). https://doi.org/10.1007/s40278-018-44559-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-018-44559-2

Search

Navigation